Asia: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Asia

The Asian prophylactic medicaments containing insulin market expanded significantly to $X in 2022, surging by 5.4% against the previous year. Over the period under review, consumption recorded a buoyant increase. Over the period under review, the market reached the peak level at $X in 2020; however, from 2021 to 2022, consumption remained at a lower figure.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Asia

In value terms, prophylactic medicaments containing insulin production reached $X in 2022 estimated in export price. Overall, production continues to indicate a prominent expansion. The pace of growth appeared the most rapid in 2013 when the production volume increased by 37%. Over the period under review, production hit record highs at $X in 2020; however, from 2021 to 2022, production stood at a somewhat lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports in Asia

In 2022, overseas shipments of medicaments containing insulin but not antibiotics in measured doses increased by 25% to X tons, rising for the second consecutive year after seven years of decline. Over the period under review, exports posted a pronounced increase. The growth pace was the most rapid in 2013 with an increase of 82% against the previous year. As a result, the exports reached the peak of X tons. From 2014 to 2022, the growth of the exports remained at a somewhat lower figure.

In value terms, prophylactic medicaments containing insulin exports dropped markedly to $X in 2022. Overall, exports recorded a significant expansion. The growth pace was the most rapid in 2021 with an increase of 105% against the previous year. As a result, the exports attained the peak of $X, and then declined sharply in the following year.

Exports by Country

India (X tons) and China (X tons) were the key exporters of medicaments containing insulin but not antibiotics in measured doses in 2022, recording near 39% and 29% of total exports, respectively. Turkey (X tons) ranks next in terms of the total exports with a 13% share, followed by the United Arab Emirates (9.6%) and Malaysia (4.9%). Singapore (X tons) held a little share of total exports.

From 2012 to 2022, the most notable rate of growth in terms of shipments, amongst the leading exporting countries, was attained by Singapore (with a CAGR of +173.5%), while the other leaders experienced more modest paces of growth.

In value terms, China ($X) remains the largest prophylactic medicaments containing insulin supplier in Asia, comprising 75% of total exports. The second position in the ranking was held by India ($X), with a 9.1% share of total exports. It was followed by Malaysia, with a 6.2% share.

From 2012 to 2022, the average annual growth rate of value in China stood at +50.7%. In the other countries, the average annual rates were as follows: India (-1.6% per year) and Malaysia (+39.2% per year).

Export Prices by Country

In 2022, the export price in Asia amounted to $X per ton, reducing by -32.2% against the previous year. Overall, the export price, however, showed resilient growth. The most prominent rate of growth was recorded in 2015 when the export price increased by 74%. Over the period under review, the export prices attained the maximum at $X per ton in 2021, and then declined significantly in the following year.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was China ($X per ton), while the United Arab Emirates ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by India (+5.2%), while the other leaders experienced more modest paces of growth.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports in Asia

In 2022, overseas purchases of medicaments containing insulin but not antibiotics in measured doses decreased by -11.9% to X tons, falling for the second year in a row after five years of growth. Total imports indicated a prominent increase from 2012 to 2022: its volume increased at an average annual rate of +5.4% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, imports decreased by -13.2% against 2020 indices. The pace of growth was the most pronounced in 2013 with an increase of 24%. The volume of import peaked at X tons in 2020; however, from 2021 to 2022, imports stood at a somewhat lower figure.

In value terms, prophylactic medicaments containing insulin imports dropped sharply to $X in 2022. Over the period under review, imports, however, recorded a relatively flat trend pattern. The pace of growth appeared the most rapid in 2016 when imports increased by 8.1% against the previous year. Over the period under review, imports hit record highs at $X in 2021, and then contracted rapidly in the following year.

Imports by Country

In 2022, Turkey (X tons), distantly followed by Japan (X tons), China (X tons), Pakistan (X tons), Saudi Arabia (X tons), Iran (X tons) and South Korea (X tons) represented the main importers of medicaments containing insulin but not antibiotics in measured doses, together constituting 70% of total imports. Indonesia (X tons), Thailand (X tons), India (X tons), the Philippines (X tons), Israel (X tons) and Vietnam (X tons) took a relatively small share of total imports.

From 2012 to 2022, the most notable rate of growth in terms of purchases, amongst the main importing countries, was attained by India (with a CAGR of +34.1%), while imports for the other leaders experienced more modest paces of growth.

In value terms, the largest prophylactic medicaments containing insulin importing markets in Asia were Japan ($X), China ($X) and India ($X), with a combined 40% share of total imports. Saudi Arabia, Turkey, Iran, South Korea, Pakistan, Vietnam, Israel, Indonesia, the Philippines and Thailand lagged somewhat behind, together accounting for a further 42%.

In terms of the main importing countries, Iran, with a CAGR of +24.3%, saw the highest growth rate of the value of imports, over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

The import price in Asia stood at $X per ton in 2022, waning by -11.5% against the previous year. Over the period under review, the import price showed a pronounced setback. The growth pace was the most rapid in 2021 when the import price increased by 5%. Over the period under review, import prices attained the peak figure at $X per ton in 2012; however, from 2013 to 2022, import prices failed to regain momentum.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was India ($X per ton), while Turkey ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Pakistan (+14.6%), while the other leaders experienced mixed trends in the import price figures.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :